Adlai Nortye (ANL) Competitors $1.72 -0.06 (-3.10%) Closing price 10/3/2025 03:55 PM EasternExtended Trading$1.72 0.00 (0.00%) As of 10/3/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ANL vs. TNYA, FENC, KYTX, VYGR, IMMP, TLSA, AVTE, JMAC, NGNE, and RENBShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Tenaya Therapeutics (TNYA), Adherex Technologies (FENC), Kyverna Therapeutics (KYTX), Voyager Therapeutics (VYGR), Prima BioMed (IMMP), Tiziana Life Sciences (TLSA), Aerovate Therapeutics (AVTE), Maxpro Capital Acquisition (JMAC), Neurogene (NGNE), and Lunai Bioworks (RENB). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Its Competitors Tenaya Therapeutics Adherex Technologies Kyverna Therapeutics Voyager Therapeutics Prima BioMed Tiziana Life Sciences Aerovate Therapeutics Maxpro Capital Acquisition Neurogene Lunai Bioworks Adlai Nortye (NASDAQ:ANL) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment. Which has preferable valuation & earnings, ANL or TNYA? Adlai Nortye has higher revenue and earnings than Tenaya Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M12.69-$51.87MN/AN/ATenaya TherapeuticsN/AN/A-$111.13M-$0.96-1.69 Is ANL or TNYA more profitable? Adlai Nortye's return on equity of 0.00% beat Tenaya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Tenaya Therapeutics N/A -93.83%-75.66% Do analysts prefer ANL or TNYA? Adlai Nortye presently has a consensus target price of $9.00, suggesting a potential upside of 423.26%. Tenaya Therapeutics has a consensus target price of $6.25, suggesting a potential upside of 285.80%. Given Adlai Nortye's higher probable upside, analysts plainly believe Adlai Nortye is more favorable than Tenaya Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Tenaya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has more risk & volatility, ANL or TNYA? Adlai Nortye has a beta of -0.87, meaning that its stock price is 187% less volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 3.15, meaning that its stock price is 215% more volatile than the S&P 500. Does the media refer more to ANL or TNYA? In the previous week, Adlai Nortye had 2 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 4 mentions for Adlai Nortye and 2 mentions for Tenaya Therapeutics. Adlai Nortye's average media sentiment score of 1.02 beat Tenaya Therapeutics' score of 0.99 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenaya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of ANL or TNYA? 35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 48.7% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryAdlai Nortye beats Tenaya Therapeutics on 7 of the 12 factors compared between the two stocks. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyeMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.84M$3.36B$6.13B$10.58BDividend YieldN/A2.28%5.67%4.69%P/E RatioN/A22.1486.8826.71Price / Sales12.69458.33605.32131.81Price / CashN/A47.8637.9061.31Price / Book2.499.9312.556.55Net Income-$51.87M-$52.80M$3.31B$277.50M7 Day Performance-0.58%5.22%4.28%2.42%1 Month Performance-1.71%10.61%6.90%8.63%1 Year Performance-8.51%25.03%70.54%31.60% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye1.9562 of 5 stars$1.72-3.1%$9.00+423.3%-10.9%$63.84M$5M0.00127News CoveragePositive NewsShort Interest ↓Gap DownTNYATenaya Therapeutics3.1799 of 5 stars$1.62+2.5%$6.25+285.8%-8.5%$264.02MN/A-1.69110News CoverageFENCAdherex Technologies2.0315 of 5 stars$9.36+3.0%$13.33+42.5%+113.9%$261.24M$47.54M-22.2910News CoverageAnalyst UpgradeKYTXKyverna Therapeutics2.2326 of 5 stars$6.00+1.0%$16.60+176.7%+19.2%$259.50M$7.03M-1.6396VYGRVoyager Therapeutics3.7112 of 5 stars$4.67-0.8%$13.25+183.7%-31.0%$259.05M$80M-2.52100IMMPPrima BioMed1.0427 of 5 stars$1.75-2.2%$7.00+300.0%-9.3%$256.88M$6.69M0.002,021TLSATiziana Life Sciences0.5014 of 5 stars$2.16+1.4%N/A+97.0%$252.40MN/A0.008AVTEAerovate TherapeuticsN/A$8.62+1.7%N/A-87.7%$249.85MN/A-2.8820High Trading VolumeJMACMaxpro Capital AcquisitionN/A$18.43flatN/AN/A$247.52MN/A0.002,021NGNENeurogene1.775 of 5 stars$17.33-2.1%$46.17+166.4%-54.0%$247.33MN/A-4.0290News CoverageAnalyst ForecastRENBLunai Bioworks0.5973 of 5 stars$1.42+12.2%N/A-68.5%$244.41MN/A-1.8420Stock SplitGap DownHigh Trading Volume Related Companies and Tools Related Companies Tenaya Therapeutics Alternatives Adherex Technologies Alternatives Kyverna Therapeutics Alternatives Voyager Therapeutics Alternatives Prima BioMed Alternatives Tiziana Life Sciences Alternatives Aerovate Therapeutics Alternatives Maxpro Capital Acquisition Alternatives Neurogene Alternatives Lunai Bioworks Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANL) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANL Stock Alerts